Clinical bottom line
Achieving a functional cure in chronic hepatitis B (CHB)—defined as sustained hepatitis B surface antigen (HBsAg) loss with or without seroconversion—remains a key therapeutic goal to reduce long-term liver-related morbidity and mortality. Recent advances in antiviral therapy and immunomodulation have improved rates of functional cure, but it remains uncommon with current nucleos(t)ide analogues (NAs). Emerging data highlight the importance of host immune responses and novel treatment strategies to enhance durable viral control. Long-term follow-up studies confirm that functional cure is associated with improved clinical outcomes, but challenges remain in identifying predictors and optimizing treatment regimens (Zheng J et al., 2025; De Broucker et al., 2025).
What the evidence shows
Zheng J et al. (2025) review factors influencing functional cure in CHB, emphasizing that effective restoration of both innate and adaptive immunity is critical. They discuss mechanisms by which current therapies suppress viral replication but often fail to eliminate covalently closed circular DNA (cccDNA), the viral reservoir.
De Broucker et al. (2025) provide long-term follow-up data in children with CHB, demonstrating that spontaneous or treatment-induced functional cure leads to sustained HBsAg loss and reduced progression to cirrhosis or hepatocellular carcinoma (HCC). Their findings underscore the durability and clinical benefit of functional cure.
Zheng P et al. (2023) detail immune pathways involved in CHB pathogenesis and highlight potential therapeutic targets to enhance immune-mediated viral clearance.
Lee Soon Kyu et al. (2025) discuss the long-term safety and efficacy of tenofovir alafenamide (TAF), noting its favorable tolerability profile but limited impact on increasing functional cure rates, thus reinforcing the need for novel agents.
Vatan Aslı et al. (2026) explore biomarkers such as the pan-immune-inflammation value to predict functional cure in patients on long-term NA therapy, suggesting potential tools for personalized treatment.
Chang J et al. (2014), although older, remain authoritative in outlining therapeutic strategies aiming for functional cure, including combination therapies and immune modulators.
Caveats and uncertainty
Functional cure rates remain low with current standard-of-care NAs, often below 10%, necessitating prolonged therapy.
Heterogeneity in patient populations, viral genotypes, and immune status complicates prediction of functional cure.
Long-term safety and efficacy data for emerging immunomodulatory agents are limited.
Optimal timing and combination of antiviral and immune-based therapies require further investigation.
Biomarkers predicting functional cure are promising but not yet validated for routine clinical use.
How this may change practice
Clinicians should continue to prioritize viral suppression with NAs while recognizing the limitations regarding functional cure.
Emerging biomarkers may aid in identifying patients most likely to achieve functional cure and guide treatment duration.
Integration of novel immunotherapies and combination regimens may become standard as evidence matures.
Long-term monitoring post-HBsAg loss remains essential to detect relapse or HCC risk.
Patient counseling should emphasize the evolving nature of functional cure strategies and the importance of adherence.
Multidisciplinary care involving hepatology, virology, and immunology expertise will be critical for personalized management.